Whitelaw Compliance Group to Attend West Chester University & Grow PA Discussion about Ethical Decision Making

On Thursday, September 27, 2018,  Whitelaw Compliance Group will be attending the open discussion hosted by West Chester University and Grow PA.  The discussion will focus on how to provide students with ethical tools to meet future employer needs.  It takes place at West Chester University.  For more information click the link.

Have Your Cake & Write a Script Too

Stepping out of her car, Sally Pharmrep glanced again at her watch.  If she was late, it would not be well received.  Reaching into the back seat of her white, four-door Camry, she pulled out the large sheet cake and, of course, the balloons.  After all, it was Dr. ThoughtLeader’s birthday and he loved balloons. . . This is neither a law school case study nor a piece of ancient compliance history. …

UnitedHealth pushes back in whistleblower case

Check out my commentary in Saturday’s (April 14th) Business Section of the Minneapolis Star Tribune.

MISSING THE MARKET: GOVERNMENT STANDARDS ARE UNDERMINING COMPLIANCE EFFORTS IN SMALLER LIFE SCIENCE COMPANIES

First introduced into life sciences more than two decades ago as the result of a government settlement, compliance officers and compliance departments are now considered essential for pharmaceutical and medical device companies. Without them, life science companies stand little chance of successfully navigating and managing the legal and compliance risks inherent in this highly regulated industry. However, the life sciences industry is no longer dominated by large market cap companies.…

A Bright Future or Unfulfilled Promise – An Update on Biosimilars and Their Prospects for Contributing to Meaningful Cost Reduction

Biosimilars have a bright future and promise potentially significant health care cost savings, provided the regulatory, legal and commercial hurdles are removed. Recent activity by CVS and United Healthcare are promising signs that indeed the commercial barriers are starting to come down. However, it remains unclear whether the FDA will help on the regulatory front.   CLICK HERE TO DOWNLOAD A FREE COPY OF THE FULL ARTICLE.